Biologics and small molecules in patients with scalp psoriasis: a systematic review

Alsenaid, Adel; Ezmerli, M.; Srour, Jerome; Heppt, Markus V.; Illigens, Ben Min-Woo; Prinz, J. C.

doi:10.1080/09546634.2020.1770167

Cited by 9 publications

(20 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…6,12,[15][16][17] Apremilast showed good tolerability with adverse events (AEs) being mild or moderate (nausea, diarrhea, and headache). 18 The LIBERATE study, a global IIIb, multicenter, RCT study in biologic-naïve patients with moderate to severe plaque psoriasis compared the efficacy and safety of apremilast, etanercept, and placebo. 19,20 In total, 250 patients were randomized to receive placebo (n = 84), etanercept 50 mg QW (n = 83), or apremilast 30 mg BID (n = 83) for 16 weeks.…”

Section: Methodsmentioning

confidence: 99%

“…19,20 Of enrolled patients, 166 had moderate or severe scalp psoriasis (ScPGA score ≥3), placebo (n = 58), apremilast (n = 54), and etanercept (n = 54). 19,20 [18][19][20] In the UNVEIL study, a phase IV RCT, secondary endpoints included the percentage of patients with scalp psoriasis that achieved a ScPGA score of 0 or 1 with a reduction of ≥2-point from baseline. 21,22 Two hundred and twenty-one patients received apremilast 30 mg BID or placebo for 16 weeks.…”

Section: Methodsmentioning

confidence: 99%

“…7,18,36 A total of 105 patients with a baseline PSSI >0 were randomized to either placebo, or different dosage of ixekizumab (10,25,75, and 150 mg). 7,18,36 The first assessment at…”

Section: Ixekizumabmentioning

confidence: 99%

“…7,18,36 In the open-label extension period, the week 48 evaluation reported a complete clearance in 81.3% of the placebo-ixekizumab and 77.3% of ixekizumab-ixekizumab groups. 7,18,36 Further phase III trials included the UNDERCOVER-1, Investigations on the pediatric populations were carried out too. 41 The IXORA-PEDS phase III trial included patients aged from 6 to 17 years and treated with the pediatric dosage of ixekizumab (weight-based) versus placebo.…”

Section: Ixekizumabmentioning

confidence: 99%

“…Apremilast is an oral phosphoriesterase‐4 inhibitor which acts by increasing the intracellular cyclic adenosine monophosphate levels, regulating the production of proinflammatory and anti‐inflammatory mediators 11 . The efficacy of apremilast in scalp psoriasis has been demonstrated in three phase III, one phase IV, and two real‐life studies 6,12‐26 …”

Section: Small Moleculesmentioning

confidence: 99%

See 4 more Smart Citations

Therapeutic update of biologics and small molecules for scalp psoriasis: a systematic review

Camela

Ocampo‐Garza

Cinelli

et al. 2021

Dermatologic Therapy

View full text Add to dashboard Cite

Scalp psoriasis represents the most common difficult-to-treat area in psoriasis patients. Its presence is linked to severe discomfort and impairment of quality of life given the associated symptoms (most of all, scaling and pruritus) and the location in a highly visible area, thus a prompt treatment is required. Its management may be challenging as the scalp is quite sensitive to long-term treatment with topical corticosteroids and usually resistant to topical and systemic agents. Likely, the currently available therapeutic armamentarium has been enriched with biologicals and small molecules that revolutionized psoriasis treatment and that of scalp psoriasis. Nevertheless, the lack of international dedicated guidelines pushed us to perform a comprehensive review on the efficacy and safety of biologics and small molecules on scalp psoriasis with the aim to put the basis for a therapeutic algorithm. After reviewing all the available evidence on the short-term and long-term efficacy of biologics and small molecules on scalp psoriasis the use of the newest biologics (anti-IL-17 and anti-IL-23) seems to be linked to the highest clinical performances in controlling scalp psoriasis. However, head-to-head comparisons between different biologics or biologics and small molecules are lacking. Hence, treatment selection should always be individualized.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

“…7,18,36 A total of 105 patients with a baseline PSSI >0 were randomized to either placebo, or different dosage of ixekizumab (10,25,75, and 150 mg). 7,18,36 The first assessment at…”

Section: Ixekizumabmentioning

confidence: 99%

Section: Ixekizumabmentioning

confidence: 99%

Section: Small Moleculesmentioning

confidence: 99%

See 3 more Smart Citations

Therapeutic update of biologics and small molecules for scalp psoriasis: a systematic review

Camela

Ocampo‐Garza

Cinelli

et al. 2021

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

Dermatoses of the Scalp

Farrant,

Mowbray,

Takwale

2024

Rook's Textbook of Dermatology

View full text Add to dashboard Cite

The scalp is a common site for several common inflammatory skin conditions, including seborrhoeic dermatitis and psoriasis. In severe cases these may be associated with hair loss. Inflammation in the dermis may cause secondary hair loss and alterations to the scalp, with thickening, folding and mucinosis. The scalp is a common site for primary skin tumours and secondary metastases. Lastly, the scalp can be associated with localised itch and pain or dysaesthesia. All of these are discussed in this chapter on the dermatoses of the scalp.

show abstract